Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Change in Acquisitions & Divestments (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Change in Acquisitions & Divestments for 12 consecutive years, with $240.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments fell 20.59% to $240.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.1 billion, a 25.49% increase, with the full-year FY2025 number at $1.1 billion, up 25.49% from a year prior.
  • Change in Acquisitions & Divestments was $240.1 million for Q4 2025 at Madrigal Pharmaceuticals, down from $275.1 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $302.4 million in Q4 2024 to a low of $12.0 million in Q1 2023.
  • A 5-year average of $151.0 million and a median of $116.6 million in 2023 define the central range for Change in Acquisitions & Divestments.
  • Peak YoY movement for Change in Acquisitions & Divestments: tumbled 87.18% in 2023, then skyrocketed 1422.61% in 2024.
  • Madrigal Pharmaceuticals' Change in Acquisitions & Divestments stood at $70.5 million in 2021, then rose by 12.33% to $79.2 million in 2022, then skyrocketed by 43.69% to $113.8 million in 2023, then skyrocketed by 165.75% to $302.4 million in 2024, then decreased by 20.59% to $240.1 million in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Change in Acquisitions & Divestments are $240.1 million (Q4 2025), $275.1 million (Q3 2025), and $273.4 million (Q2 2025).